FDA Panel Sparks Major Industry Shift: Why Hims Stock and the Peptide Boom Are Taking ...

An FDA advisory panel voted to allow compounding pharmacies to produce peptides like BPC-157 and TB-500, moving these compounds from an unregulated gray market toward clinical supervision. Telemedicine platforms including Hims & Hers are positioned to capture significant market share as regulatory clarity enables broader commercialisation.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.